Authors
Seok Jin Kim, Chiun Hsu, Yu-Qin Song, Kevin Tay, Xiao-Nan Hong, Junning Cao, Jin Seok Kim, Hyeon Seok Eom, Joon Hyeok Lee, Jun Zhu, Kian-Meng Chang, Arry Harryanto Reksodiputro, Daryl Tan, Yeow Tee Goh, Jejung Lee, Tanin Intragumtornchai, Wee-Joo Chng, Ann-Lii Cheng, Soon Thye Lim, Cheolwon Suh, Yok-Lam Kwong, Won Seog Kim
Publication date
2013/11/1
Journal
European journal of cancer
Volume
49
Issue
16
Pages
3486-3496
Publisher
Pergamon
Description
Background
Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas.
Methods
Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n = 340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n = 127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis.
Results
HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving …
Scholar articles
SJ Kim, C Hsu, YQ Song, K Tay, XN Hong, J Cao… - European journal of cancer, 2013